Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TBT $ODYY getting ready for breakout!!!JMHO
$ODYY Getting ready for next level!!
$ODYY Settling in and ready for next move!!!
$ODYY Twitter heating up!! Watch for more action and price appreciation as the word gets out!! Got you back BTW
$ODYY Twitter feed heating up!!!
Odyssey Group International
@OdysseyGroupIn1
We develop and acquire life saving medical products with a technological and clinical advantage.
OTCQB: $ODYY
#ConcussionAwareness
Irvine, Californiaodysseygi.comJoined January 2021
613 Following
356 Followers
$ODYY Twitter feed heating up!!!
Odyssey Group International
@OdysseyGroupIn1
We develop and acquire life saving medical products with a technological and clinical advantage.
OTCQB: $ODYY
#ConcussionAwareness
Irvine, Californiaodysseygi.comJoined January 2021
613 Following
356 Followers
$ODYY up 50% this week!!!
$ODYY running up 50%this week
$ODYY HUGE NEWS OUT!!!
Odyssey Group International Receives Donation to Support a Treatment for Concussion and forms Community Partnership with the Erase PTSD Now Foundation
IRVINE, CA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced that it has received a donation in the amount of $500,000 in partnership with the Erase PTSD Now organization and the Glenn Greenberg and Linda Vester Foundation. These funds will be used to progress the Phase 1 human clinical trials for drug candidate PRV-002 for the treatment of concussion.
“We are honored to have formed a partnership with Erase PTSD Now and to have been chosen by Glenn and Linda’s Foundation for such a tremendous gift to advance our drug trials. We are currently in a Phase I safety study and these funds will allow us to make significant progress and prepare for the Phase II trials,” commented Michael Redmond, CEO of Odyssey Group International.
“We have a highly respected record of helping Post-Traumatic Stress Disorder (PTSD) patients. We are excited to work with Odyssey and our PTSD sufferers to better understand the link between concussion and PTSD. Like Odyssey’s scientific team, we believe that if our veterans are treated early on with a brain-targeted agent they will have better psychological outcomes,” commented, Dr. Eugene Lipov, Chief Scientific Officer of Erase PTSD Now Foundation.
Glen and Linda have a passion for helping military veterans. They recognize the unique medical conditions they face and how vital it is that they receive specialty care. Unfortunately, many veterans develop PTSD. PTSD symptoms can include unwanted memories, depression, anxiety, avoidance behaviors and panic disorder. Worst of all, PTSD is associated with a higher incidence of suicide. Glenn and Linda’s Foundation works directly with the Erase PTSD Now Foundation. Erase PTSD Now provides funding for the sympathetic modulation procedure. This procedure has a very high efficacy rate in reducing PTSD symptoms and mental health dysfunction, as well as improving quality of life.
Concussions have been linked to the increased incidence of PTSD. Odyssey is developing the first pharmaceutical to treat concussion in the acute phase of injury. A field deliverable intranasal device filled with their drug, PRV-002 can be kept in the medic’s bag or the soldier’s pocket for “buddy” aid immediately following a concussion. Reducing inflammation of the brain early on can significantly improve outcomes and return our soldiers back to action faster and more safely.
Odyssey Group International and Erase PTSD Now have formed a community-based partnership to collect data on PTSD patients who have also sustained a concussion. Measures for patient symptom severity, short-term memory and thought processing speed will be the cornerstone for better understanding the link between these two conditions. This partnership will benefit PTSD patients by helping them understand how brain trauma can lead to psychological sequelae and assist Odyssey in the design of future military arms of their clinical trials.
For more information about the Erase PTSD NOW organization, visit their website at https://eraseptsdnow.org/.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC Pink: ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners. Odyssey is changing its name to Odyssey Health, Inc. to reflect our corporate mission and focus.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the Phase 1 trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Group International
Preya Narain
info@odysseygi.com
https://www.globenewswire.com/newsroom/ti?nf=ODQyMzg0MCM0NjQ3MDk5IzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/Mjc0YWUxMmItYWY4OS00ZjUwLThmZGEtMjYwZjgzMGRmMGMwLTUwMDA4NjI2NA==/tiny/Odyssey-Group-Intl-Inc-.png
Source: Odyssey Group Intl Inc.
© 2022 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Open Market Logo
Pink Current Information
Verified Profile IconVerified Profile 08/2021
Transfer Agent Verified IconTransfer Agent Verified
Shell Risk IconShell Risk
Independent Directors IconIndependent Directors
$ODYY HUGE NEWS OUT!!!
Odyssey Group International Receives Donation to Support a Treatment for Concussion and forms Community Partnership with the Erase PTSD Now Foundation
IRVINE, CA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced that it has received a donation in the amount of $500,000 in partnership with the Erase PTSD Now organization and the Glenn Greenberg and Linda Vester Foundation. These funds will be used to progress the Phase 1 human clinical trials for drug candidate PRV-002 for the treatment of concussion.
“We are honored to have formed a partnership with Erase PTSD Now and to have been chosen by Glenn and Linda’s Foundation for such a tremendous gift to advance our drug trials. We are currently in a Phase I safety study and these funds will allow us to make significant progress and prepare for the Phase II trials,” commented Michael Redmond, CEO of Odyssey Group International.
“We have a highly respected record of helping Post-Traumatic Stress Disorder (PTSD) patients. We are excited to work with Odyssey and our PTSD sufferers to better understand the link between concussion and PTSD. Like Odyssey’s scientific team, we believe that if our veterans are treated early on with a brain-targeted agent they will have better psychological outcomes,” commented, Dr. Eugene Lipov, Chief Scientific Officer of Erase PTSD Now Foundation.
Glen and Linda have a passion for helping military veterans. They recognize the unique medical conditions they face and how vital it is that they receive specialty care. Unfortunately, many veterans develop PTSD. PTSD symptoms can include unwanted memories, depression, anxiety, avoidance behaviors and panic disorder. Worst of all, PTSD is associated with a higher incidence of suicide. Glenn and Linda’s Foundation works directly with the Erase PTSD Now Foundation. Erase PTSD Now provides funding for the sympathetic modulation procedure. This procedure has a very high efficacy rate in reducing PTSD symptoms and mental health dysfunction, as well as improving quality of life.
Concussions have been linked to the increased incidence of PTSD. Odyssey is developing the first pharmaceutical to treat concussion in the acute phase of injury. A field deliverable intranasal device filled with their drug, PRV-002 can be kept in the medic’s bag or the soldier’s pocket for “buddy” aid immediately following a concussion. Reducing inflammation of the brain early on can significantly improve outcomes and return our soldiers back to action faster and more safely.
Odyssey Group International and Erase PTSD Now have formed a community-based partnership to collect data on PTSD patients who have also sustained a concussion. Measures for patient symptom severity, short-term memory and thought processing speed will be the cornerstone for better understanding the link between these two conditions. This partnership will benefit PTSD patients by helping them understand how brain trauma can lead to psychological sequelae and assist Odyssey in the design of future military arms of their clinical trials.
For more information about the Erase PTSD NOW organization, visit their website at https://eraseptsdnow.org/.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC Pink: ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners. Odyssey is changing its name to Odyssey Health, Inc. to reflect our corporate mission and focus.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the Phase 1 trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Group International
Preya Narain
info@odysseygi.com
https://www.globenewswire.com/newsroom/ti?nf=ODQyMzg0MCM0NjQ3MDk5IzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/Mjc0YWUxMmItYWY4OS00ZjUwLThmZGEtMjYwZjgzMGRmMGMwLTUwMDA4NjI2NA==/tiny/Odyssey-Group-Intl-Inc-.png
Source: Odyssey Group Intl Inc.
© 2022 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Open Market Logo
Pink Current Information
Verified Profile IconVerified Profile 08/2021
Transfer Agent Verified IconTransfer Agent Verified
Shell Risk IconShell Risk
Independent Directors IconIndependent Directors
HUGE NEWS FOR $ODYY!!! Thanks Fun
$ODYY Volume and price moving!!
$ODYY Volume and price moving!!
I like it when shares get returned to treasury. Guess they're not just giving shares away. JMHO GLTY $ODYY
$ODYY Something brewing. Biggest volume day in months...
$ODYY something brewing. biggest volume day in months
Someone acquiring shares hmmmmmm $ODYY
NEWS OUT!!! $ODYY
Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device
Press Release | 10/19/2021
IRVINE, CA, Oct. 19, 2021 (GLOBE NEWSWIRE) --
Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, today announced the filing of a provisional patent on its novel nasal drug delivery device. The device and drug combination will be used in Odyssey’s sponsored current clinical trial for treating concussion.
Odyssey’s breath powered nasal device is equipped with a novel dual wall drug dispensing system that creates a unique dual airflow for depositing concentrated drug deep into the nasal cavity and onto the olfactory region for direct diffusion into the brain for the treatment of nasal and/or central nervous system (“CNS”) injury, disease or disorder, especially brain injury, such as traumatic brain injury (“TBI”), namely, concussion.
The specialty design can be seen in Figure 1 below. The nasal end of the device is designed to enhance the propulsion of the powdered drug into the superior portion of the nasal cavity where the olfactory neurons are located therefore increasing the amount of drug transported directly to the brain. By increasing the depth of drug dispersion, more drug is realized in the superior portion of the nasal cavity where brain access is available. The act of blowing closes the soft palate in the back of the throat preventing the drug from being inhaled or passing into the digestive system and therefore reducing systemic side effects. Most importantly the closing of soft palate traps the drug in the nasal cavity allowing it to stick to the superior nasal membranes and then diffuse directly into the brain by way of the olfactory nerve.
“The ability to get PRV-002 into the brain rapidly after concussion while simultaneously having less concern for side effects will be instrumental to our success in clinical trials. This novel breath-propelled nasal device gives Odyssey that opportunity. Odyssey is interested in bringing other neurological drugs into our portfolio that can also benefit from this nasal device specialization,” commented Michael Redmond, CEO of Odyssey Group International.
Figure 1
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC:ODYY) is a technology company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
NEWS OUT!!! $ODYY
Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device
Press Release | 10/19/2021
IRVINE, CA, Oct. 19, 2021 (GLOBE NEWSWIRE) --
Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, today announced the filing of a provisional patent on its novel nasal drug delivery device. The device and drug combination will be used in Odyssey’s sponsored current clinical trial for treating concussion.
Odyssey’s breath powered nasal device is equipped with a novel dual wall drug dispensing system that creates a unique dual airflow for depositing concentrated drug deep into the nasal cavity and onto the olfactory region for direct diffusion into the brain for the treatment of nasal and/or central nervous system (“CNS”) injury, disease or disorder, especially brain injury, such as traumatic brain injury (“TBI”), namely, concussion.
The specialty design can be seen in Figure 1 below. The nasal end of the device is designed to enhance the propulsion of the powdered drug into the superior portion of the nasal cavity where the olfactory neurons are located therefore increasing the amount of drug transported directly to the brain. By increasing the depth of drug dispersion, more drug is realized in the superior portion of the nasal cavity where brain access is available. The act of blowing closes the soft palate in the back of the throat preventing the drug from being inhaled or passing into the digestive system and therefore reducing systemic side effects. Most importantly the closing of soft palate traps the drug in the nasal cavity allowing it to stick to the superior nasal membranes and then diffuse directly into the brain by way of the olfactory nerve.
“The ability to get PRV-002 into the brain rapidly after concussion while simultaneously having less concern for side effects will be instrumental to our success in clinical trials. This novel breath-propelled nasal device gives Odyssey that opportunity. Odyssey is interested in bringing other neurological drugs into our portfolio that can also benefit from this nasal device specialization,” commented Michael Redmond, CEO of Odyssey Group International.
Figure 1
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC:ODYY) is a technology company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase 1clinical, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital
Primary Logo
Here’s Your Chance to Get in Early on What Could Be the Next Amazon
Sponsored By: The Motley Fool
5 Stocks the World’s Smartest Investors Are Buying to Prepare for the Possible Retail Apocalypse. Read More
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Open Market Logo
Pink Current Information
Verified Profile IconVerified Profile 08/2021
Transfer Agent Verified IconTransfer Agent Verified
Shell Risk IconShell Risk
Independent Directors IconIndependent Directors
$ODYY To begin Clinical Trials
Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion
Press Release | 09/22/2021
IRVINE, CA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a medical company focused on developing unique, life-saving medical products, today announced successful completion of their clinical trial site initiation visit and the start of subject screening and enrollment. The drug candidate PRV-002 is being developed to treat concussion as a novel neurosteroid delivered nasally. Odyssey’s Phase 1 clinical trial status can be viewed at www.clinicaltrials.gov.
“We are so excited to start enrollment for our human trials and establish a strong safety profile following PRV-002 nasal application. These studies will look at pharmacokinetics and drug tolerability at 3 dosage strengths. The most tolerated dose will be used in the subsequent trials to determine efficacy,” commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
Odyssey screening and enrollment of subjects coincides with the completion of their Phase 1 clinical batch of PRV-002. The spray dried material has been filled in its unique breath-propelled nasal applicator and is being shipped this week to the trial site in preparation for first cohort dosing. Each device is uniquely labeled by the manufacturer to comply with the double-blinded nature of the study.
“We have a long history of managing successful Phase 1 clinical trials. We are excited to be enrolling subjects and look forward to administering PRV-002 and identifying a safe drug dosage based on tolerability and pharmacokinetics. We feel Odyssey’s unique breath-propelled drug-device combination will promote enrollment while the community need for a concussion treatment should enhance compliance. Concussion is an unmet need that needs to see an effective treatment get approved.” stated, Philip Ryan, MD, Principal Investigator at Nucleus Network, Inc.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase 1 trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital
$ODYY To begin Clinical Trials
Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion
Press Release | 09/22/2021
IRVINE, CA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a medical company focused on developing unique, life-saving medical products, today announced successful completion of their clinical trial site initiation visit and the start of subject screening and enrollment. The drug candidate PRV-002 is being developed to treat concussion as a novel neurosteroid delivered nasally. Odyssey’s Phase 1 clinical trial status can be viewed at www.clinicaltrials.gov.
“We are so excited to start enrollment for our human trials and establish a strong safety profile following PRV-002 nasal application. These studies will look at pharmacokinetics and drug tolerability at 3 dosage strengths. The most tolerated dose will be used in the subsequent trials to determine efficacy,” commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
Odyssey screening and enrollment of subjects coincides with the completion of their Phase 1 clinical batch of PRV-002. The spray dried material has been filled in its unique breath-propelled nasal applicator and is being shipped this week to the trial site in preparation for first cohort dosing. Each device is uniquely labeled by the manufacturer to comply with the double-blinded nature of the study.
“We have a long history of managing successful Phase 1 clinical trials. We are excited to be enrolling subjects and look forward to administering PRV-002 and identifying a safe drug dosage based on tolerability and pharmacokinetics. We feel Odyssey’s unique breath-propelled drug-device combination will promote enrollment while the community need for a concussion treatment should enhance compliance. Concussion is an unmet need that needs to see an effective treatment get approved.” stated, Philip Ryan, MD, Principal Investigator at Nucleus Network, Inc.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase 1 trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital
Primary Logo
See why they call M1 the Finance Super App—and why hundreds of thousands of investors have joined.
Sponsored By : M1 Finance
There is no better way to invest, borrow, or spend your hard-earned wealth than with M1 Finance. With great rates, powerful tools, and tons of flexibility, M1 is the all-in-one app you need to supercharge how you manage your money. Read More
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Current Information
Verified Profile 08/2021
Transfer Agent Verified
Shell Risk
Independent Directors
$ODYY NEWS OUT!!
Odyssey Group International Completes Final Drug-Device Combination Product in Preparation for Clinical Trial Launch
Press Release | 08/30/2021
IRVINE, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique medical products, today announced the successful completion of their novel drug-device combination product to be administered in human clinical trials for treating concussion.
After sustaining a concussion there is brain swelling, inflammation and oxidative stress. Odyssey has developed a drug formulation designed to reduce this harmful response. The drug formula can be given via breath propulsion into the nose. As a spray-dried powder formulation, the active drug can be dispersed throughout the upper portion of the nasal cavity without being inhaled or swallowed. The drug-device combination allows for the drug to travel upward along the cranial nerves used for smell and is delivered directly into the traumatized brain.
The final powdered formula has been completed and certified by Upperton Limited, a GMP drug manufacturer based in the UK. Particle size to be dispersed from the device has been defined. Upperton is now filling, packaging and labeling the drug-device combination product in preparation for Odyssey’s Phase 1 clinical trial.
“By developing our drug formulation in powder form we can ensure all regions of the nasal cavity are exposed thus increasing the amount absorbed into the brain. We believe this novel formulation will not only lead to greater drug efficacy but with our targeted approach reduce exposure and any potential side effects to other organs of the body.” commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
“We are excited that we have been able to optimize and begin manufacturing Odyssey’s concussion drug formula for human trials. Our expertise in manufacturing drugs into spray-dried powder form is used to maximize drug performance and safety. It’s exciting to be involved in such a novel drug administration design.” Said Paul Kelsall, Director of Clinical Manufacturing, Upperton Limited, Inc.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the ethics committee review process, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
$ODYY NEW OUT!!
Odyssey Group International Completes Final Drug-Device Combination Product in Preparation for Clinical Trial Launch
Press Release | 08/30/2021
IRVINE, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique medical products, today announced the successful completion of their novel drug-device combination product to be administered in human clinical trials for treating concussion.
After sustaining a concussion there is brain swelling, inflammation and oxidative stress. Odyssey has developed a drug formulation designed to reduce this harmful response. The drug formula can be given via breath propulsion into the nose. As a spray-dried powder formulation, the active drug can be dispersed throughout the upper portion of the nasal cavity without being inhaled or swallowed. The drug-device combination allows for the drug to travel upward along the cranial nerves used for smell and is delivered directly into the traumatized brain.
The final powdered formula has been completed and certified by Upperton Limited, a GMP drug manufacturer based in the UK. Particle size to be dispersed from the device has been defined. Upperton is now filling, packaging and labeling the drug-device combination product in preparation for Odyssey’s Phase 1 clinical trial.
“By developing our drug formulation in powder form we can ensure all regions of the nasal cavity are exposed thus increasing the amount absorbed into the brain. We believe this novel formulation will not only lead to greater drug efficacy but with our targeted approach reduce exposure and any potential side effects to other organs of the body.” commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
“We are excited that we have been able to optimize and begin manufacturing Odyssey’s concussion drug formula for human trials. Our expertise in manufacturing drugs into spray-dried powder form is used to maximize drug performance and safety. It’s exciting to be involved in such a novel drug administration design.” Said Paul Kelsall, Director of Clinical Manufacturing, Upperton Limited, Inc.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the ethics committee review process, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
NEWS OUT!! $ODYY
Odyssey Group International Completes Final Drug-Device Combination Product in Preparation for Clinical Trial Launch
Press Release | 08/30/2021
IRVINE, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique medical products, today announced the successful completion of their novel drug-device combination product to be administered in human clinical trials for treating concussion.
After sustaining a concussion there is brain swelling, inflammation and oxidative stress. Odyssey has developed a drug formulation designed to reduce this harmful response. The drug formula can be given via breath propulsion into the nose. As a spray-dried powder formulation, the active drug can be dispersed throughout the upper portion of the nasal cavity without being inhaled or swallowed. The drug-device combination allows for the drug to travel upward along the cranial nerves used for smell and is delivered directly into the traumatized brain.
The final powdered formula has been completed and certified by Upperton Limited, a GMP drug manufacturer based in the UK. Particle size to be dispersed from the device has been defined. Upperton is now filling, packaging and labeling the drug-device combination product in preparation for Odyssey’s Phase 1 clinical trial.
“By developing our drug formulation in powder form we can ensure all regions of the nasal cavity are exposed thus increasing the amount absorbed into the brain. We believe this novel formulation will not only lead to greater drug efficacy but with our targeted approach reduce exposure and any potential side effects to other organs of the body.” commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
“We are excited that we have been able to optimize and begin manufacturing Odyssey’s concussion drug formula for human trials. Our expertise in manufacturing drugs into spray-dried powder form is used to maximize drug performance and safety. It’s exciting to be involved in such a novel drug administration design.” Said Paul Kelsall, Director of Clinical Manufacturing, Upperton Limited, Inc.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the ethics committee review process, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
I'm sure she deserves it. There's a lot of paperwork required by the FDA.
I don't think there would be this many well known celebrities endorsing something that doesn't work. JMHO
Yes they are time consuming, but these lottery ticket drug companies are worth the wait IMO...
FUN NEWS OUT!!!
Odyssey Group International Completes IND-enabling Studies, Submits Investigator’s Brochure for Phase 1 Clinical Trial
Press Release | 08/04/2021
IRVINE, CA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the successful completion of their Investigational New Drug (“IND”) enabling studies and submission of their Investigator’s Brochure (“IB”) for Ethics Committee review to begin Phase 1 clinical trials for the first in-human treatment of concussion.
“Having successfully completed our IND-enabling studies and Investigational Brochure we have taken a large step closer to launching human clinical trials for a potential treatment for this unmet medical need,” commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
The IB includes the pre-clinical safety and efficacy data, the design for Phase 1 clinical trials and the informed consent to enroll subjects in the trial. Furthermore, the IB requires that IND-enabling studies be successfully completed and reported. These study areas include the following: Safety Pharmacology, Toxicology, CMC (Chemistry Manufacturing and Control) activities, ADME (Absorption, Distribution, Metabolism and Excretion) and Genotoxicity. The Ethics Committee is expected to complete their review this month.
“PRV-002 continues to pass all the required steps to enter human trials. Successful completion of these IND-enabling studies provides confidence that our drug is safe, active and stable.” said Michael Redmond, CEO of Odyssey Group International
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the ethics committee review process, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital
Primary Logo
GDET NEWS OUT!!!!
GD Entertainment & Technology’s (GDET) Launches Dual Crypto™ Dreamcard, The World’s First-to-Market Multifunctional Crypto/Fiat Debit Card
Press Release | 06/30/2021
Fort Lee, New Jersey, June 30, 2021 (GLOBE NEWSWIRE) -- GD Entertainment and Technology (OTC Pink: GDET) (“GDET” or the “Company”) (https://gdetco.com), a Company focused on high growth industries related to the Crypto Space, is pleased to announce that it has officially launched its Dual Crypto™ Dreamcard, the world’s first Crypto/Fiat Dual Debit/Credit Card, containing a dual-chip and issued as a notably sleek polished metal card.
The dual chip allows the user to carry their Crypto in “Cold Storage”, while simultaneously connecting to their wallet, with instant access use via the Fiat function of their Dual Crypto™ Dreamcard.
GDET’s Dual Crypto™ Dreamcard allows a user secure access to multiple accounts everywhere they go. Cryptocurrency is a rapidly growing space with an ever-increasing number of vendors and venues willing to accept it, and our Dual Crypto™ Dreamcard is both first-to-market and right on time for a burgeoning demand for this type of functionality.”
As well, GDET has re-designed its DreamCard website, www.dreamcard.cc This site allows a user to swap out securely their plastic debit or credit card for a high-quality card, available in lustrous metal colors with several design options, or flaunt-worthy 24-karat gold designs based on user preferences.
GO METAL WITH $GDET DREAMCARD:
ODYY NEWS OUT!!
Odyssey Group International Reports Achieving Drug Safety Standards for Clinical Trials of its Drug for Treating Concussion
8:30 am ET June 29, 2021 (Globe Newswire) Print
Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products today announced the successful completion of their final system safety studies and cellular safety assays for entering clinical trials to treat concussion. The Company's drug, PRV-002, will now receive a final safety review by the Clinical Trial Ethics Committee.
"Safety is of the utmost importance when performing a clinical trial with a novel drug compound. We are comfortable and excited to move forward into the clinic now that we have demonstrated how safe PRV-002 is across the board," commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
The cardiac receptor, hERG, which maintains electrical homeostasis was assayed with PRV-002. Findings showed no significant cardiac liability at proposed concussion treatment concentrations. Further there was no appreciable mutagenesis or cancer-like activity when evaluating PRV-002 using the Ames Test at clinically defined treatment concentrations. Additionally, respiratory toxicology testing was done in rodents with results showing no effect of PRV-002 on Respiratory Rate, Tidal Volume or Minute Volume.
In a separate test of the nasal applicator device, established quality control protocols proved effective with no bacterial or viral contamination.
"Combined, these safety findings are very favorable for PRV-002 as a clinical trial drug candidate" commented Michael Redmond, CEO. The Odyssey Group International concussion drug development program can now receive its final safety review by the Ethics Committee to move forward into human trials.
IMTL Huge NEWS!!!
Hip-Hop and Crypto Mogul Jim Jones Signs with Image Protect’s (IMTL) Celebrity NFT Platform; Website Launching This Week
Press Release | 06/29/2021
New York, New York, June 29, 2021 (GLOBE NEWSWIRE) -- Image Protect Inc. (OTC Pink: IMTL) (https://imageprotect.com/) ("Image Protect", "IMTL", or the "Company"), an emerging Media Company, is pleased to announce the official signing of hip hop Legend, Television Star, Entrepreneur, and entertainment mogul Jim Jones (https://twitter.com/jimjonescapo) to its NFT Marketplace, Legends NFT, an evolution of Fotofy which launches in full this week.
The Company’s partnership with celebrity photographer Idris Erba (www.idriserba.com) has Erba set to shoot exclusive high-profile images of Jones for Legends NFT where the Company will feature the highest level NFTs, (Non-Fungible Tokens) for fans and investors alike.
Shareholders can check out the front-end today at https://legendnfts.io, and the full site launches live later this week with its blockchain in ERC 20 token readied for the auction process. The Company utilizes https://greenlight.digital, a top tier crypto consulting group, for its back-end build out and managing the auction process.
CEO Lawrence Adams stated, “We are elated to have such an Impactful talent to our NFT site, Jim has been a dominant force in the development and growth in Hip Hop over the years, and has built a lasting legacy, I’m confident we’ll capture digitally that energy he brings through his music and produce a collection that will exist for years to come”.
As well, Jones joins IMTL’s platform with an existing affinity for cryptocurrency and NFTs. Between ventures in the cannabis industry, with Capo-Saucy Extract Farms, his Vampire Life clothing line and the newly launched Quarantine Studios, Jones has created several revenue streams over the years by identifying and investing in emerging markets, including his recently minted $CapoCoin in partnership with Zaptheory — which is essentially a social marketplace for cryptocurrency and NFT’s, like Ethereum.
In 2021 alone, NFT’s, which can be collectible items or a string of events, have exploded within the music industry as artists such as Post Malone, MF DOOM, and Lil Pump all have announced NFT experiences of their own.
JIM JONES is Top American rapper, record executive, and music video director. Jones is an original member of hip hop collective the Diplomats (also known as Dipset), is also the co-CEO of Diplomat Records, alongside longtime friend and fellow Harlem-bred rapper, Cam'ron. Jones is also a noted music video director under the pseudonym CAPO, having directed videos for artists including Cam'ron, Juelz Santana, Remy Ma and State Property.
In 2004, he released his debut solo album On My Way to Church. The release of his second album, Harlem: Diary of a Summer in 2005, coincided with Jones landing an executive position in A&R at Entertainment One Music. A year later he was on his third album Hustler's P.O.M.E. (Product of My Environment) (2006), which spawned his biggest single to date, "We Fly High". The song reached number five on the US Billboard Hot 100 chart and was certified platinum by the Recording Industry Association of America (RIAA).
In 2006, Jones also formed the hip hop group and label ByrdGang. The group released their debut album M.O.B.: The Album, under the newly found label in 2008. Jones followed up with his first major-label album Pray IV Reign, which was released in March 2009, under Columbia Records. The album spawned the hit single "Pop Champagne". In April 2011, Jones released his fifth album, Capo, which was supported by the lead single, "Perfect Day". He returned in May 2019, for his sixth album titled El Capo.
About Image Protect:
Image Protect is a media company with a focus on microcap news, information, and disclosure, as well as crypto, blockchain, and digital assets. The Company recently signed to acquire OTC PR Wire, LLC, a revenue stage service provider and news platform catering to microcap and small cap companies on a global scale. Its unique digital asset library and proprietary technology via subsidiary Fotofy. are conducive to the foundation of an impactful NFT marketplace.
Safe Harbor Provision
Cautionary statement for purposes of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995: Information in this news release contains forward-looking statements that involve risks, uncertainties and assumptions. If such risks or uncertainties materialize or such assumptions prove incorrect, the results of the Company and its consolidated subsidiaries could differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Risks, uncertainties and assumptions include the execution and performance of contracts by the Company and its customers, suppliers and partners. The Company disclaims any obligation to update or revise statements contained in this news release based on new information or otherwise.
Corporate Contact:
Image Protect
Preya Narain
Preya.Narain@imageprotect.com
Good to see they're staying current. Would like to see another Corporate update. $ODYY
NEWS OUT!! $ODYY
Odyssey Group International Announces Successful Toxicology Studies for its Concussion Drug
Press Release | 05/26/2021
IRVINE, CA, May 26, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of the Food and Drug Administration (FDA) required toxicology studies designed to support clinical trials with PRV-002, its lead drug candidate to treat concussion (mild traumatic brain injury). Odyssey has also contracted with a Contract Research Organization (CRO) for its planned Phase 1 human trial.
PRV-002 was tested in two species of laboratory animals, dosed three times per day at three escalating doses by intranasal administration for 14 days. Standard safety assessments included laboratory blood tests, urinalysis, EKG, clinical observations and detailed microscopic evaluation of all major organs. These preclinical studies demonstrated that the safety margin of PRV-002 was over 100-fold that of intended safety and efficacious dosing in clinical trials. This key data positions Odyssey to initiate human clinical testing this summer.
Odyssey’s Phase 1 clinical trials will be performed in Australia with the assistance of Nucleus Network. Inc., a leading CRO. Phase 1 clinical trial data collected in Australia is accepted by the FDA and provides Odyssey a 43% rebate on trial costs from the Australian government. These data will strengthen the Company’s Investigational New Drug Application (IND) with the FDA prior to starting Phase 2 trials back in the US. Additional preclinical studies required by the FDA have either been completed, are currently ongoing or will be completed prior to the IND submission to the FDA for phase 2.
“This is an important step in the development of our concussion drug and prepares us for clinical trials,” commented Michael Redmond, President and Chief Executive Officer of Odyssey Group International. “The toxicology results suggest tremendous safety related to our drug and we are excited to partner with an esteemed CRO such as Nucleus Network to move forward with the Phase 1 trials.”
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
odyy@cg.capita
NEWS OUT!! $ODYY
Odyssey Group International Announces Successful Toxicology Studies for its Concussion Drug
Press Release | 05/26/2021
IRVINE, CA, May 26, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of the Food and Drug Administration (FDA) required toxicology studies designed to support clinical trials with PRV-002, its lead drug candidate to treat concussion (mild traumatic brain injury). Odyssey has also contracted with a Contract Research Organization (CRO) for its planned Phase 1 human trial.
PRV-002 was tested in two species of laboratory animals, dosed three times per day at three escalating doses by intranasal administration for 14 days. Standard safety assessments included laboratory blood tests, urinalysis, EKG, clinical observations and detailed microscopic evaluation of all major organs. These preclinical studies demonstrated that the safety margin of PRV-002 was over 100-fold that of intended safety and efficacious dosing in clinical trials. This key data positions Odyssey to initiate human clinical testing this summer.
Odyssey’s Phase 1 clinical trials will be performed in Australia with the assistance of Nucleus Network. Inc., a leading CRO. Phase 1 clinical trial data collected in Australia is accepted by the FDA and provides Odyssey a 43% rebate on trial costs from the Australian government. These data will strengthen the Company’s Investigational New Drug Application (IND) with the FDA prior to starting Phase 2 trials back in the US. Additional preclinical studies required by the FDA have either been completed, are currently ongoing or will be completed prior to the IND submission to the FDA for phase 2.
“This is an important step in the development of our concussion drug and prepares us for clinical trials,” commented Michael Redmond, President and Chief Executive Officer of Odyssey Group International. “The toxicology results suggest tremendous safety related to our drug and we are excited to partner with an esteemed CRO such as Nucleus Network to move forward with the Phase 1 trials.”
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
odyy@cg.capita
NEWS OUT!! $ODYY
Odyssey Group International Announces Successful Toxicology Studies for its Concussion Drug
Press Release | 05/26/2021
IRVINE, CA, May 26, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of the Food and Drug Administration (FDA) required toxicology studies designed to support clinical trials with PRV-002, its lead drug candidate to treat concussion (mild traumatic brain injury). Odyssey has also contracted with a Contract Research Organization (CRO) for its planned Phase 1 human trial.
PRV-002 was tested in two species of laboratory animals, dosed three times per day at three escalating doses by intranasal administration for 14 days. Standard safety assessments included laboratory blood tests, urinalysis, EKG, clinical observations and detailed microscopic evaluation of all major organs. These preclinical studies demonstrated that the safety margin of PRV-002 was over 100-fold that of intended safety and efficacious dosing in clinical trials. This key data positions Odyssey to initiate human clinical testing this summer.
Odyssey’s Phase 1 clinical trials will be performed in Australia with the assistance of Nucleus Network. Inc., a leading CRO. Phase 1 clinical trial data collected in Australia is accepted by the FDA and provides Odyssey a 43% rebate on trial costs from the Australian government. These data will strengthen the Company’s Investigational New Drug Application (IND) with the FDA prior to starting Phase 2 trials back in the US. Additional preclinical studies required by the FDA have either been completed, are currently ongoing or will be completed prior to the IND submission to the FDA for phase 2.
“This is an important step in the development of our concussion drug and prepares us for clinical trials,” commented Michael Redmond, President and Chief Executive Officer of Odyssey Group International. “The toxicology results suggest tremendous safety related to our drug and we are excited to partner with an esteemed CRO such as Nucleus Network to move forward with the Phase 1 trials.”
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
odyy@cg.capital
Primary Logo
More importantly is that Australian clinical's ARE RECOGNIZED by the FDA!!! Hang in there!!!$ODYY
From their PR!!
The nasal device will be used in phase 1 clinical trials being scheduled in Australia this summer.
But Clinical's are on the way...$ODYY
$TQLB NEWS OUT!!!
Torque's American Metabolix Adds Key Influencer Mariam Olivera, Social Media Icon & Athlete with 2.3M Followers
Newsfile Corp.
Newsfile Corp
Wheat Ridge, Colorado--(Newsfile Corp. - March 17, 2021) - Torque Lifestyle Brands Inc. (OTC Pink: TQLB) ("Torque" or the "Company"), (www.torquelb.com) an emerging leader in the active lifestyle sports nutrition and supplements marketplace, is excited to announce that the Company has signed up-and-coming social media superstar Mariam Olivera as a key influencer helping to promote its American Metabolix (www.americanmetabolix.com) branded line of products.
Olivera has more than 2.3 million social media followers and fans across multiple platforms, including more than 1.9 million followers on Instagram, where she has cultivated a stunning 7.11% engagement rate - according to Digitalmarketingcommunity.com, the average Instagram engagement rate by audience is 1.22%.
Mariam Olivera is a top influencer on both Instagram (@mariam_olv) and TikTok (@mariam_olv). She will be doing Instagram posts and stories for American Metabolix as well as TikTok videos with swipe-ups for ordering from the American Metabolix website.
"Mariam is a perfect complement to American Metabolix because she has credibility as a health & fitness advocate and model, and she can reach a massive audience with very little overlap with our other marketing activities," commented Leonard K. Armenta Jr, President of Torque. "She is a phenomenal social media presence with a rapidly growing brand and a level of engagement with her base that you rarely come across. She will pack a punch with her posts, and we anticipate a clear impact."
Torque recently closed its acquisition of American Metabolix and its branded line of leading sports nutrition products, which are sold in over 550 brick and mortar locations across multiple countries, including the United States, New Zealand, Australia, and Russia, among others.
About Torque Lifestyle Brands Inc.
Torque Lifestyle Brands Inc. (OTC Pink: TQLB) is focused on driving performance through acquisitions and by advancing original brands in the rapidly growing supplemental nutrition marketplace.
Cautionary Statement Regarding Forward-Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding departure of the company's CEO. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target," "intend" and "expect" and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Corporate Contact:
invest@torquelb.com
Investor Relations Contact:
EDM Media, LLC
https://edm.media
(800) 301-7883
$ODYY NEWS OUT!! This could go viral!!!
Odyssey Group International Announces Formation of Sports Advisory Board to Enhance Awareness of Traumatic Brain Injuries and Concussions
Press Release | 03/17/2021
IRVINE, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce the formation of a Sports Advisory Board (SAB) to increase awareness regarding the unmet medical need for a treatment for brain injuries including concussion. The Company is in the pre-clinical phase of development of a drug compound (PRV-002) and is preparing for its first human clinical trial. The inaugural members of the SAB include notable professional athletes who have a passion to advance treatments for brain injuries:
Kurt Warner – NFL Hall of Fame, NFL MVP, Super Bowl MVP, Super Bowl Champion
Brett Favre – NFL Hall of Fame Quarterback, Super Bowl Champion, 3x consecutive MVP
Mark Rypien – 2x Super Bowl Champion, 1st Canadian quarterback to start in the NFL
David Ross – Current Manager of the Chicago Cubs, 2x World Series Champion catcher
Steve “Mooch” Mariucci – Head coach San Francisco 49er’s from 1997-2002 and Detroit Lions from 2003-2005, current member of the NFL’s Player Safety Advisory Committee.
The SAB will support Odyssey’s outreach efforts to enhance public awareness of traumatic brain injuries and concussion as well as the need for an FDA approved therapy.
Michael Redmond, CEO of Odyssey said, “We are pleased to announce the formation of our Sports Advisory Board during Brain Injury Awareness month. Each of these new members have been directly affected by traumatic brain injury and have first-hand experience of its effects on health and quality of life. Concussion is a major health issue not only in sports but also in the military and in everyday life. Our sports advisory board will play an integral role in enhancing the public’s awareness and understanding of the impacts of this common condition for which there is currently no FDA-approved drug treatment. We believe that if we successfully develop and commercialize PRV-002, we will be able to significantly improve outcomes for concussion patients.”
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital